Treatment

Tozorakimab-placebo clinical trials

4 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)
This study is looking at a new medicine called Tozorakimab for people with COPD. It aims to see if it can reduce severe flare-ups and if it's safe. Participants will be compared to those taking a dummy medicine.
For: Chronic Obstructive Pulmonary Disease (COPD)
Czechia · Denmark · Bulgaria
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TITANIA)
This study is testing a new medicine, Tozorakimab, for people with severe COPD who often have flare-ups. We want to see if it reduces these flare-ups and is safe to use. Some people will get the new medicine, others a dummy medicine (placebo).
For: Chronic Obstructive Pulmonary Disease (COPD)
Poland · Germany · Italy
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)
This study is testing a new medicine called Tozorakimab for people with severe COPD. It aims to see if Tozorakimab can reduce flare-ups and is safe to use long-term, compared to a dummy medicine.
For: Chronic Obstructive Pulmonary Disease (COPD)
Sweden · Romania · Spain
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)
This study is testing a new medicine, tozorakimab, for people with lung disease called COPD. It wants to see if this medicine can help reduce flare-ups of COPD. Some people will get the new medicine, and others will get a dummy medicine, alongside their usual care.
For: Chronic Obstructive Pulmonary Disease (COPD)
Greece · Denmark · Netherlands

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)